Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focusing on AAV-based gene therapies for severe monogenic CNS diseases, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). On October 1, 2024, the Compensation Committee of Taysha's Board of Directors granted a new employee an option to purchase 501,600 shares of the company's common stock.
The stock option, granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan, has an exercise price of $2.02 per share, equal to the closing price on the grant date. It has a 10-year term and will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), un'azienda biotecnologica in fase clinica specializzata in terapie geniche basate su AAV per malattie CNS monogeniche gravi, ha annunciato una concessione di indennità ai sensi della Regola di Quotazione Nasdaq 5635(c)(4). Il 1° ottobre 2024, il Comitato Compensi del Consiglio di Amministrazione di Taysha ha concesso a un nuovo dipendente un'opzione per acquistare 501.600 azioni delle azioni ordinarie della società.
L'opzione sulle azioni, concessa nell'ambito del Piano di Indennità 2023 di Taysha Gene Therapies, Inc., ha un prezzo di esercizio di $2,02 per azione, pari al prezzo di chiusura nella data di concessione. Ha un termine di 10 anni e si maturerà nel corso di quattro anni, con il 25% che si matura al primo anniversario e il restante 75% che si matura in rate mensili uguali nei successivi 36 mesi, subordinato a un servizio continuato.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), una empresa de biotecnología en etapa clínica enfocada en terapias génicas basadas en AAV para enfermedades monogénicas graves del SNC, ha anunciado una concesión de incentivos bajo la Regla de Cotización 5635(c)(4) de Nasdaq. El 1 de octubre de 2024, el Comité de Compensación de la Junta Directiva de Taysha otorgó a un nuevo empleado una opción para comprar 501,600 acciones de las acciones ordinarias de la compañía.
La opción de acciones, otorgada bajo el Plan de Incentivos 2023 de Taysha Gene Therapies, Inc., tiene un precio de ejercicio de $2.02 por acción, igual al precio de cierre en la fecha de concesión. Tiene un plazo de 10 años y se consolidará durante cuatro años, con un 25% consolidándose en el primer aniversario y el 75% restante consolidándose en cuotas mensuales iguales durante los siguientes 36 meses, sujeto a un servicio continuo.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA)는 심각한 단일 유전 CNS 질환을 위한 AAV 기반 유전자 치료에 초점을 맞춘 임상 단계의 생명공학 기업으로, Nasdaq 상장 규칙 5635(c)(4)에 따른 유인 보상을 발표했습니다. 2024년 10월 1일, Taysha의 보상 위원회는 새로운 직원에게 회사의 보통주 501,600주를 구매할 수 있는 옵션을 부여했습니다.
이 옵션은 Taysha Gene Therapies, Inc. 2023 유인 계획에 따라 부여되었으며, 행사 가격은 주당 $2.02로, 부여일의 종가와 동일합니다. 이 옵션은 10년의 기간을 가지며, 4년에 걸쳐 분할된 베스팅 조건을 포함하고, 첫 번째 기념일에 25%가 베스팅되고 나머지 75%는 다음 36개월 동안 동일한 월별 할부로 베스팅되며, 계속적인 서비스가 조건입니다.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), une entreprise de biotechnologie en phase clinique se concentrant sur les thérapies géniques basées sur AAV pour les maladies cérébrales monogéniques graves, a annoncé une attribution incitative en vertu de la Règle de Cotation Nasdaq 5635(c)(4). Le 1er octobre 2024, le Comité de Rémunération du Conseil d'Administration de Taysha a accordé à un nouvel employé une option d'achat de 501 600 actions des actions ordinaires de la société.
L'option d'achat d'actions, accordée dans le cadre du Plan d'Attribution Incitative 2023 de Taysha Gene Therapies, Inc., a un prix d'exercice de 2,02 $ par action, correspondant au prix de fermeture à la date d'attribution. Elle a un terme de 10 ans et sera acquise sur quatre ans, avec 25 % acquises lors du premier anniversaire et les 75 % restants acquises en versements mensuels égaux au cours des 36 mois suivants, sous réserve d'un service continu.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf AAV-basierte Gentherapien für schwere monogene ZNS-Erkrankungen spezialisiert hat, hat eine Anreizgewährung gemäß der Nasdaq-Notierungsregel 5635(c)(4) angekündigt. Am 1. Oktober 2024 gewährte der Vergütungsausschuss des Vorstands von Taysha einem neuen Mitarbeiter die Option, 501.600 Aktien der Stammaktien des Unternehmens zu erwerben.
Die Aktienoption, die im Rahmen des 2023 Anreizplans von Taysha Gene Therapies, Inc. gewährt wurde, hat einen Ausübungspreis von $2,02 pro Aktie, was dem Schlusskurs am Gewährungstag entspricht. Sie hat eine Laufzeit von 10 Jahren und wird über vier Jahre hinweg fällig, wobei 25% am ersten Jahrestag fällig werden und die verbleibenden 75% in gleichen monatlichen Raten über die nächsten 36 Monate fällig werden, vorausgesetzt, der Dienst wird fortgesetzt.
- Taysha granted a significant stock option of 501,600 shares to a new employee, potentially attracting top talent
- The stock option has a 10-year term, providing long-term incentive for employee retention
- The stock option grant may lead to potential dilution for existing shareholders
DALLAS, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2024, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 501,600 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has an exercise price of
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
FAQ
What is the exercise price of the stock option granted by Taysha Gene Therapies (TSHA) on October 1, 2024?
How many shares were included in the stock option grant by Taysha Gene Therapies (TSHA) on October 1, 2024?
What is the vesting schedule for the stock option granted by Taysha Gene Therapies (TSHA) on October 1, 2024?
Under which plan was the stock option granted by Taysha Gene Therapies (TSHA) on October 1, 2024?
